The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Sponsor
Chinese PLA General Hospital
Study ID
NCT03007446
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib :A starting dose of apatinib was administered 500 mg daily
  • Oxaliplatin — DRUG
    Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
  • S-1 — DRUG
    S-1:40mg，bid，d1-14，po，in a 21 day cycle.

Study Details

This is a Prospective，Single-center，Single-arm，Open-label exploratory clinical trial evaluating the efficacy and safety of Conversion Surgery for Apatinib plus SOX for patients with unresectable gastric cancer.

Key Dates

Start date
Nov 30, 2016
Status verified
Sep 2017
Primary completion
Nov 30, 2018
Completion
Nov 30, 2018

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib plus Oxaliplatin/S-1
    1. Apatinib : A starting dose of apatinib was administered 500 mg daily on days 1 through 21 of each 3-week cycle. 2. Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle. 3. S-1:40mg，bid，d1-14，po，in a 21 day cycle.

Primary Outcome Measure

reaction rate [ Time Frame: 4 months ]

Central Contacts

  • Hongqing Xi, Master
    010-66938128

Related Studies